Global Alzheimer’s Disease Diagnostic Market is Expected to Grow at a CAGR of 8.90% from 2023 to 2032

Pune, India, February 23, 2023 /MRFR Press Release/- Market Research Future published a half-cooked research report on Global Alzheimer’s Disease Diagnostic Market. 

Market Highlights
Global Alzheimer’s Disease Diagnostic Market size to reach USD 8.8 billion by 2032 at 8.90% CAGR during the forecast period 2023-2032. Alzheimer’s is a type of dementia which causes failure of the functioning of the brain. This disease damages the areas which is responsible for the thinking, problem solving and behavior process.  According to the Alzheimer’s association, more than 5 million are living with alzheimer’s and one out of three seniors dies with the Alzheimer’s or any another type of dementia.

One of the most common early symptom of Alzheimer's is difficulty remembering newly learned information. As the Alzheimer's advances through the brain it leads to increasingly severe symptoms which includes bafflement, mood and behavior swings, deepening confusion about events, time and place; unfounded thoughts about family, friends and professional caregivers and more serious memory loss and behavior changes; and difficulty speaking, swallowing and walking.

There are different types of tests to diagnose the symptoms of the alzheimer’s which includes Mini Mental State Exam (MMSE) this tests will help to know whether there are problems with the areas of brain involved in learning, memory, thinking, or planning skills. Other one is brain imaging which includes CT scan, Magnetic Resonance Imaging (MRI); Neuropsychological Testing and genetic tests which provide information regarding the incorrect linking of the genes which causes Alzheimer’s among others.

The development of therapeutic methods and the primary new approvals of drugs that will drive growth during the forecast period which will supplement current market players and offer greater therapeutic options to the patients.

Global Alzheimer’s disease Diagnostic market:

The Global Alzheimer’s disease diagnostic market has been evaluated as a growing market and it is expected that the market will touch high growth figures in future. Factors such rising efforts on research and development by the players to treat Alzheimer’s disease and the introduction of the blockbuster drugs into the market to cure the disease will drive the growth of the market. The global Alzheimer’s disease diagnostic market is expected to grow with CAGR of ~10% during the forecasted period.

Explore In-depth Details: Alzheimer’s Disease Diagnostic Market Research Report

Key Players:

The major participants of this market are: Eli Lilly and Company (UK), TauRx (Republic of Singapore), Alector LLC (US), Accera, Inc. (US), Treventis Corporation (US), Neuro-Bio Ltd (UK), Cognition Therapeutics Inc. (US) and others.

Regional Analysis:

Depending on geographic region, Alzheimer’s disease diagnostic market is segmented into four key regions: North America, Europe, Asia Pacific, and Middle East & Africa. Globally North America is the largest market for Alzheimer’s disease as they deploy the most advanced techniques and increasing demand for the cost effective products. Europe is the second-largest market for Alzheimer’s disease. Asia pacific region is expected to be fastest growing region in alzheimer’s disease diagnostic market due to increasing spending on healthcare infrastructure and acceptance of the advanced products in this region.

Segmentation:

Global Alzheimer’s disease diagnostic market has been segmented on the basis of type which comprises of early-onset alzheimer's, late-onset alzheimer's, familial Alzheimer’s disease and others. On the basis of diagnostic tests; market is segmented into genetic testing, neurological exam, mini-mental state exam (MMSE), brain imaging and others. On the basis of end users; market is segmented into clinics, hospitals, diagnostic centers and others.